Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unique perception of clinical trials by Korean cancer patients.
Lee SJ, Park LC, Lee J, Kim S, Choi MK, Hong JY, Park S, Maeng CH, Chang W, Kim YS, Park SH, Park JO, Lim HY, Kang WK, Park YS. Lee SJ, et al. Among authors: park s, park ys, park lc, park sh, park jo. BMC Cancer. 2012 Dec 12;12:594. doi: 10.1186/1471-2407-12-594. BMC Cancer. 2012. PMID: 23234342 Free PMC article.
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee.
Kim MJ, Kim YS, Oh SY, Lee S, Choi YJ, Seol YM, Park MJ, Kim KH, Park LC, Kang JH, Hwang IG, Lee SI, Lim ST, Kim HS, Lim HY, Rha SY, Kim HJ. Kim MJ, et al. Among authors: park mj, park lc. Korean J Intern Med. 2018 Mar;33(2):383-390. doi: 10.3904/kjim.2015.162. Epub 2016 Apr 6. Korean J Intern Med. 2018. PMID: 27048257 Free PMC article.
A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.
Kim YS, Ji JH, Oh SY, Lee S, Huh SJ, Lee JH, Song KH, Son CH, Roh MS, Lee GW, Lee J, Kim ST, Kim CK, Jang JS, Hwang IG, Ahn HK, Park LC, Oh SY, Kim SG, Lee SC, Lim DH, Lee SI, Kang JH. Kim YS, et al. Among authors: park lc. Oncologist. 2020 Jan;25(1):e186-e193. doi: 10.1634/theoncologist.2019-0221. Epub 2019 Sep 6. Oncologist. 2020. PMID: 31492766 Free PMC article. Clinical Trial.
A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J, Park S, Jung HA, Lee SH, Seo S, Kim SB, Kim JW, Lee KW, Kang EJ, Kim JW, Choi YJ, Shim BY, An HJ, Park LC, Shin SH, Kim JJ, Oh SY, Kim MK, Ahn MJ. Lee J, et al. Among authors: park lc. Cancer. 2023 Oct 1;129(19):2966-2974. doi: 10.1002/cncr.34892. Epub 2023 May 28. Cancer. 2023. PMID: 37246414 Free article. Clinical Trial.
A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer.
Seo S, Keam B, Shin SH, Chae YS, Kim TM, Park LC, Hong SB, Ahn MJ, Kim SB. Seo S, et al. Among authors: park lc. Int J Cancer. 2023 Oct 15;153(8):1501-1511. doi: 10.1002/ijc.34622. Epub 2023 Jun 26. Int J Cancer. 2023. PMID: 37357950 Clinical Trial.
86 results